Ninlaro(ixazomib)
Ninlaro (ixazomib) is a small molecule pharmaceutical. Ixazomib was first approved as Ninlaro on 2015-11-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ninlaro
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ninlaro | New Drug Application | 2025-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
HCPCS
No data
Clinical
Clinical Trials
163 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 30 | 66 | 11 | 7 | 10 | 105 |
| Plasma cell neoplasms | D054219 | — | — | 20 | 41 | 11 | 7 | 8 | 76 |
| Neutropenia | D009503 | — | D70 | — | — | — | 1 | — | 1 |
| Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | — | 1 | — | 1 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | — | — | — | 1 | — | 1 |
| Febrile neutropenia | D064147 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyloidosis | D000686 | EFO_1001875 | E85 | 4 | 4 | 1 | — | 1 | 7 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | 1 | 1 | — | 1 | 4 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 2 | 3 | 1 | — | — | 4 |
| Frailty | D000073496 | — | R53.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 12 | 10 | — | — | — | 17 |
| Neoplasms | D009369 | — | C80 | 8 | 2 | — | — | — | 10 |
| Leukemia | D007938 | — | C95 | 5 | 4 | — | — | — | 8 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 5 | 3 | — | — | 1 | 7 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 5 | 1 | — | — | — | 5 |
| Lymphoid leukemia | D007945 | — | C91 | 5 | 1 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 5 | — | — | — | 5 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 3 | — | — | — | 5 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 2 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 4 | — | — | — | 4 |
Show 49 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute disease | D000208 | — | — | 2 | — | — | — | — | 2 |
| Poems syndrome | D016878 | EFO_1001115 | — | 1 | — | — | — | — | 1 |
| Pathologic complete response | D000095384 | — | — | 1 | — | — | — | — | 1 |
| Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Neurofibrosarcoma | D018319 | — | — | 1 | — | — | — | — | 1 |
| Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | — | — | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | — | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paraproteinemias | D010265 | — | D47.2 | — | — | — | — | 1 | 1 |
| Abnormal karyotype | D059786 | — | — | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ixazomib |
| INN | ixazomib |
| Description | Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. It has a role as an apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It is a member of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids. |
| Classification | Small molecule |
| Drug class | proteozome inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O |
Identifiers
| PDB | — |
| CAS-ID | 1072833-77-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2141296 |
| ChEBI ID | — |
| PubChem CID | 25183872 |
| DrugBank | DB09570 |
| UNII ID | 71050168A2 (ChemIDplus, GSRS) |
Target
Agency Approved
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ninlaro – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,021 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,011 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use